AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05724433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual HF Care
Description: Patients will receive virtual visits for 3 months following hospitalization / emergency department (ED) visit for HF. Physiologic measures will be monitored remotely and therapies will be optimized.
Study NCT05724433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine HF Care
Description: Care as determined by the treating physician
Study NCT05091424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive subcutaneous (SC) mosunetuzumab
Study NCT05091424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab as needed for cytokine release syndrome (CRS) events.
Study NCT05091424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive daily oral venetoclax
Study NCT06534099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.
Study NCT06534099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Without changing their original lifestyle habits, weekly follow-ups were conducted by the experimenters via telephone or face-to-face interviews to ensure that the participants did not engage in other forms of regular fitness activities.
Study NCT06534099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The Wuqinxi exercise regimen was conducted under the guidance of a professional Wuqinxi instructor, where the experimental group practiced the five animal forms of the exercise, which include the Tiger, Deer, Bear, Ape, and Bird forms. The exercise period was 24 weeks, with the first 4 weeks designated as the learning phase and weeks 5 to 24 as the consolidation and reinforcement phase. The frequency of exercise was three times per week, with each session lasting 70 minutes, including 10 minutes for warm-up and relaxation activities.
Study NCT05987813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS Unit
Description: Usage of the Transcutaneous Electrical Nerve Stimulation device for 2 hours a day.
Study NCT06328036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT06328036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study NCT06328036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06328036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06328036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06328036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06328036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection
Study NCT06328036 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical resection
Study NCT06328036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given IV
Study NCT04966247 — intervention group
Intervention type: OTHER
Intervention: Microdialysis
Description: Monitoring real-time cerebral biomarkers using microdialysis method
Study NCT06328036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tiragolumab
Description: Given IV
Study NCT05214222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib/Penpulimab/Chemotherapy
Description: Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks
Study NCT05214222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab/Chemotherapy
Description: Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks Post-progression genetic testing, continued treatment: Anlotinib,Penpulimab Anlotinib: Once daily, one capsule per time (10mg for weight \<60KG, 12mg for weight ≥60KG), administered from day 1 to day 14 of each cycle. Two consecutive weeks of treatment followed by one week off, 3 weeks per treatment cycle.~Penpulimab: 200mg, administered on day 1 of each cycle, every 3 weeks.
Study NCT04878094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravenous Indocyanine Green/ICG injection
Description: Intravenous Indocyanine Green/ICG injection will be administered for visualization
Study NCT04878094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PINPOINT endoscopic fluorescence imaging system
Description: After resection the surgeon will use the PINPOINT imaging system to assess perfusion of the colonic stump. The intervention will again be used following establishment of the anastomosis, however this time via a proctoscope to visualize the proximal and distal ends of the rectosigmoid anastomosis.
Study NCT04878094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: Standard technique and assessment of anastomosis without the use of NIR angiography
Study NCT04878094 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Standard technique and assessment of anastomosis without the use of NIR angiography
Study NCT05256173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin Tablets
Description: Melatonin Tablets was given 3 tablets (6.21mg) daily at the beginning of bedtime at night for a total of 4 weeks.
Study NCT05256173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactasin Tablets
Description: The placebo group was given at the beginning of bedtime at night for a total of 4 weeks.
Study NCT05256173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: transcutaneous vagus nerve stimulation treatment, frequency 10Hz, stimulation site is the anterior wall of the left external auditory canal (tragus), used twice a day, each treatment for 30 minutes, a total of 4 weeks.
Study NCT05256173 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcutaneous vagus nerve stimulation
Description: In the sham stimulation group, the stimulation site was the left earlobe with a frequency of 10Hz, which was used twice a day for 30 minutes for a total of 4 weeks.
Study NCT06427226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10 mg tab once daily given during the duration of AC cycles.
Study NCT04808323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.
Study NCT04808323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Initial Dose of Radiation before Dose Escalation
Description: 50 Gy over 25 frac.
Study NCT04808323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort A: Dose Escalation Radiation
Description: Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.
Study NCT05043298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 360 Injection
Description: IBI 360 dose level of escalation IV Q3W Day 1
Study NCT05043298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI 360 Injection Sintilimab
Description: IBI 360 dose level of escalation IV Q3W Day 1 Sintilimab 200mg IV Q3W Day 1
Study NCT04866173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dog
Description: Subjection to standardised stress situations in the presence of a dog and a person
Study NCT04866173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Dog
Description: Subjection to standardised stress situations in the presence of a person
Study NCT05879887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPHOLDS (Utilizing Palliative Care for Heart Failure Optimized using Lay Navigators to Decrease Suffering)
Description: UPHOLDS is a multicomponent, lay palliative care coach-led supportive care intervention designed to improve quality of life in individuals with advanced heart failure. In a series of weekly, one-on-one, 15-20 minute sessions, participants receive psychoeducation on palliative care principles (problem solving, self-care, symptom management, and advanced care planning), financial coaching (orientation to normalizing financial distress, introducing healthcare-related financial terms, exploring financial needs and steps to discussing finances in care decisions, and identifying financial resources in the health system and community), a one-time specialty palliative care outpatient clinic visit, as well as monthly follow-up.
Study NCT04808323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort B: Dose Escalation Radiation
Description: Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.
Study NCT04808323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohort C: Dose Escalation Radiation
Description: Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.
Study NCT05576987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Students selected for the experimental group will be trained by the researcher for school accidents prepared in line with the components of the Health Belief Model.The training program will be planned as 30 minutes per week for 4 weeks. Before the training and at the end of the training (at the end of the 4th week), the students will be applied personal information form and a behavior scale for safety precautions in school accidents.
Study NCT04808323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)
Study NCT05987683 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture
Description: Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
Study NCT05987683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thread-Embedding Acupuncture, Sham Thread-Embedding Acupuncture
Description: Thread-Embedding Acupuncture: using a 29-gauge TEA needle with a 50-mm PDO (polydioxanone) thread Sham Thread-Embedding Acupuncture: using a 29-gauge TEA needle but thread-removed, just needle alone
Study NCT05789043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab+apatinib+TMZ
Description: camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
Study NCT05789043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camrelizumab+apatinib
Description: camrelizumab 200mg，q2w+apatinib 250mg qd
Study NCT05789043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camrelizumab
Description: camrelizumab 200mg，q2w
Study NCT06570863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotics(doxycycline)
Description: doxycycline 100 mg 2 stat the first day followed by od for 14 days
Study NCT05036499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Providing corrective normative feedback on alcohol use, psychoeducation on the interplay between pain and alcohol use, and providing exercises to target pain-related anxiety
Study NCT06365177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical consultation
Description: The subject enters a room where the therapist is present. A chair is placed against a wall in the same room.~Once again, the therapist suggests repeating the test. During the test, the therapist sits opposite the patient, at the same distance as the computer used during the teleconsultation.
Study NCT06365177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Teleconsultation
Description: Prior to the test, the investigator should carry out a mock test with a volunteer from the facility, for example, to ensure wifi, sound and image functionality.~The patient enters a room where a computer equipped with a webcam is set up on a desk. The teleconsultation has already started when the patient enters the room. No recordings are made.~A chair is placed at a distance from the desk, with the backrest against a wall. The chair faces the computer. The desk or table where the computer is located is about 3 meters from the participant, ensuring that the webcam can frame the patient's entire body during the test.~With the consultation already underway, the investigator can direct the patient to sit in the chair against the wall. The investigator will make sure that the patient hears the instructions given.~Once the patient is seated on the chair, the therapist explains the test procedure and shows it once to make sure the subject understands it.
Study NCT05388864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three-Tier Model
Description: Families in the intervention will be counseled by a pediatric provider about ACEs, resilience, stress management, and healthy relationships. Families will also be referred to community health workers and parenting educators.
Study NCT06570863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotic powder of Lactobacillus Reuteri. After mechanical debridement patient will be prescribed with Lactobacillus rhamnosus SP1 \[(2x107colony forming units (CFU)/ day)\] (Macrofood S.A., Santiago de Chile, Chile) for 1 month. The dose would be one sachet taken orally daily. The sachets presented to the patients would be identical. Individuals will be instructed to dissolve 1 sachet in water (150 mL) and ingest it once a day after brushing their teeth.
Study NCT06570863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metronidazole gel 25%
Description: After mechanical debridement, 25% of metronidazole gel was administered into the periodontal pockets. The gel was applied with a parojet syringe provided with a blunt cannula
Study NCT05001009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Implementation Strategy Stage 1: low intensity clinician training
Description: A booster of the established LSTDI implementation strategy. Clinicians will be presented with summary written/electronic materials on the LSTDI developed for the study. Online training options and when and how to complete goals of care conversations and documentation will be highlighted.
Study NCT05001009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Implementation Strategy Stage 2: high intensity clinician training
Description: This includes two components:~1. Team facilitation to help the primary care team (advance practice provider, nurse, social worker) work together to create roles and responsibilities for accomplishing goals of care conversations with patients~2. A patient list trigger of patients potentially eligible for goals of care conversations (the patient study population) will be sent to the primary care clinicians.
Study NCT06255756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week.
Study NCT06255756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine rehabilitation training
Description: Balance function training: Patients were instructed to achieve weight shift between the left and right sides of the balance bar in a standing position.~Walking function training: based on hip, knee, and ankle control training, patients were instructed to take steps training.~Core muscle strength training: Patients were instructed to maintain 3 minutes of training in Bridge-style movement.~Functional training of daily living: including training on dressing and undressing, independent eating, painting, and writing.~Routine rehabilitation training was performed 30-45 minutes/time, 1-2 times/day, 5-7 days/week.
Study NCT06255756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing rehabilitation training
Description: Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced.
Study NCT06255756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing rehabilitation training
Description: Swallowing-related organ training involves various exercises targeting the lip, mandibular muscle, cheek, tongue muscle, soft palate, as well as exercises for vocal cord closure, laryngeal lifting, and pharyngeal muscle training. These exercises are performed for 5-15 minutes each session, 1-2 times per day, and 5-7 days per week.~Sensory stimulation training is conducted using a self-made popsicle, where medical staff gently stimulate the patient's cheek, palatoquadrate, soft palate, posterior pharyngeal wall, tongue surface, and sublingual area repeatedly. Each session lasts 5-25 minutes, performed 1-3 times per day, and 3-7 days per week.~Once the patient's swallowing function improves to a certain extent, allowing for safe oral intake, direct training or oral feeding training can be gradually introduced.
Study NCT06255756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Description: The whole acupuncture therapy was performed once daily for 5 days per week, including acupuncture needle and tongue needle.~Acupuncture needle:~Main acupoints: Lianquan, Shanglianquan (depression between the hyoid bone and the lower border of the mandible), Yifeng; Auxiliary acupoints: Fengchi, Wangu, Fengfu, Yamen, Neidaying (depression of 1 inch below the anterior margin of the mandible).~Tongue needle (pricking):~Acupoints: Jinjin, Yuye, posterior pharyngeal wall (both sides of the uvula).
Study NCT06253000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
Study NCT06253000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation of pulmonary veins according to the box isolation type using a non-fluoroscopic navigation system.
Study NCT06016855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Debulking
Description: Undergo surgical debulking
Study NCT06016855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given by IV
Study NCT06016855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Computed Tomography
Study NCT06016855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo Magnetic Resonance Imaging
Study NCT06016855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 Dotatate
Description: Given by IV
Study NCT06016855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Positron Emission Tomography